MCID: SRC027
MIFTS: 58

Sarcoma, Synovial

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Sarcoma, Synovial

MalaCards integrated aliases for Sarcoma, Synovial:

Name: Sarcoma, Synovial 57 13 44 39
Synovial Sarcoma 12 73 20 58 36 29 15 17 70
Synovialosarcoma 20 58
Synovial Cell Sarcoma 20
Sarcoma Synovial 54

Characteristics:

Orphanet epidemiological data:

58
synovial sarcoma
Inheritance: Not applicable; Age of onset: All ages;

HPO:

31
sarcoma, synovial:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:5485
OMIM® 57 300813
KEGG 36 H00050
MeSH 44 D013584
NCIt 50 C3400
SNOMED-CT 67 63211008
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 71 C0039101
Orphanet 58 ORPHA3273
MedGen 41 C0039101
SNOMED-CT via HPO 68 124975008 302851001
UMLS 70 C0039101

Summaries for Sarcoma, Synovial

KEGG : 36 Synovial sarcomas account for 7% to 10% of all human soft-tissue sarcomas. The tumors arise at any age, but affect mainly young adults and more commonly males. Clinically, they appear as deep-seated slowly growing masses. In more than half of the cases, metastases develop, primarily to the lungs but also to the lymph nodes and bone marrow. A specific translocation, t(X; 18)(p11.2; q11.2), is found in more than 90% of reported synovial sarcoma, including biphasic, monophasic, and poorly differentiated tumors. The breakpoints of the t(X; 18) have been cloned and shown to involve the fusion of the SYT gene at 18q11 to either of two highly homologous genes at Xp11 called SSX1 and SSX2. The SYT-SSX1 fusion is associated with biphasic morphology and a worse prognosis, whereas the SYT-SSX2 fusion tends to show monophasic morphology and better outcome.

MalaCards based summary : Sarcoma, Synovial, also known as synovial sarcoma, is related to spindle cell synovial sarcoma and biphasic synovial sarcoma. An important gene associated with Sarcoma, Synovial is SSX2 (SSX Family Member 2), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Endometrial cancer. The drugs Dacarbazine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and kidney, and related phenotypes are synovial sarcoma and embryo

Disease Ontology : 12 A synovium cancer which develops in the synovial membrane of the joints.

GARD : 20 Synovial sarcoma is a rare and aggressive soft tissue sarcoma. In the early stages of the condition, it may cause no noticeable signs or symptoms. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. Treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy.

OMIM® : 57 Synovial sarcomas, which represent approximately 10% of all soft tissue sarcomas, are aggressive spindle cell sarcomas containing in some cases areas of epithelial differentiation. They consistently show a specific t(X;18)(p11.2;q11.2), which usually represents either of 2 gene fusions, SYT (600192)-SSX1 (312820) or SYT-SSX2 (300192), encoding putative transcriptional proteins differing at 13 amino acid positions (summary by Ladanyi et al., 2002). Synovial sarcoma, according to the experience of Enzinger and Weiss (1983), is the fourth most common type of soft tissue sarcoma. It usually develops in adolescents and young adults, is more common in males than in females, and has no racial predilection. (300813) (Updated 05-Apr-2021)

Wikipedia : 73 A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily... more...

Related Diseases for Sarcoma, Synovial

Diseases related to Sarcoma, Synovial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 523)
# Related Disease Score Top Affiliating Genes
1 spindle cell synovial sarcoma 33.2 SSX2 SSX1 SS18
2 biphasic synovial sarcoma 33.0 VIM SSX4 SSX2 SSX1 SS18 MUC1
3 epithelioid cell synovial sarcoma 33.0 SSX2 SSX1 SS18 KRT7 CTAG1B CALB2
4 monophasic synovial sarcoma 33.0 VIM SSX2 SSX1 SS18 MUC1 KRT7
5 spindle cell sarcoma 32.8 VIM SSX2 SSX1 SS18 MUC1 MDM2
6 sarcoma 32.7 VIM SSX4 SSX3 SSX2 SSX1 SS18
7 benign mesothelioma 31.6 VIM KRT7 KRT19 CALB2
8 leiomyosarcoma 31.6 VIM MUC1 MDM2 KIT
9 malignant peripheral nerve sheath tumor 31.5 VIM MUC1 MDM2 KRT7 KIT IGF1R
10 hemangiopericytoma, malignant 31.5 VIM SSX2 SSX1 SS18 MUC1 MDM2
11 neurilemmoma 31.4 VIM MUC1 KIT CALB2
12 liposarcoma 31.4 VIM MDM2 IGF1R CTNNB1 CALB2
13 ewing sarcoma 31.4 VIM SSX1 SS18 MDM2 KIT IGF1R
14 pneumothorax 31.4 VIM MUC1 CALB2
15 kidney sarcoma 31.4 SSX2 SSX1 SS18
16 rhabdomyosarcoma 31.4 VIM SSX2 SSX1 MDM2 KRT7 KIT
17 lung sarcoma 31.4 SSX2 SSX1 CALB2
18 malignant fibrous histiocytoma 31.4 VIM MUC1 MDM2
19 epithelioid sarcoma 31.3 VIM MUC1 KRT7 CALB2
20 malignant mesenchymoma 31.3 SSX2 MDM2
21 mesothelioma, malignant 31.3 VIM MUC1 KRT7 CTNNB1 CDH1 CALB2
22 carcinosarcoma 31.2 VIM MUC1 KRT7 KIT CTNNB1 CDH1
23 connective tissue benign neoplasm 31.1 MDM2 KIT CTNNB1 CALB2
24 chondrosarcoma, extraskeletal myxoid 31.1 SSX2 SSX1 SS18
25 embryonal sarcoma 31.1 VIM MDM2 KIT CTNNB1
26 neurofibroma 31.1 VIM MUC1 KIT
27 desmoplastic small round cell tumor 31.0 VIM MUC1 FLI1
28 sarcomatoid renal cell carcinoma 31.0 MUC1 MDM2 KIT CDH1
29 angiosarcoma 31.0 VIM MUC1 MDM2 KRT7 KIT FLI1
30 myxoid liposarcoma 30.9 SSX2 SSX1 SS18 MDM2 KRT19 IGF1R
31 pseudosarcomatous fibromatosis 30.9 VIM SS18 KIT CTNNB1
32 angiomyolipoma 30.9 VIM KRT7 KIT
33 dedifferentiated liposarcoma 30.9 SSX2 SS18 MUC1 MDM2 KIT IGF1R
34 cellular myxoid liposarcoma 30.9 SSX2 SSX1 SS18 MDM2 CTAG1B
35 renal cell carcinoma, nonpapillary 30.9 VIM MUC1 KRT7 KRT19 KIT IGF1R
36 papillary carcinoma 30.9 MUC1 KRT7 KRT19 CDH1 CALB2
37 secretory meningioma 30.8 VIM MUC1 KRT7
38 hemangioma 30.8 VIM MUC1 KRT7 KIT FLI1 CTNNB1
39 sarcomatoid mesothelioma 30.8 VIM MUC1 CALB2
40 mesenchymal chondrosarcoma 30.8 VIM MUC1 KRT7
41 glomus tumor 30.8 VIM MUC1 CALB2
42 small cell carcinoma 30.8 MUC1 KRT7 KRT19 KIT
43 rhabdoid cancer 30.8 VIM SSX2 SS18 MUC1 IGF1R
44 adenocarcinoma 30.7 MUC1 MDM2 KRT7 KIT IGF1R CTNNB1
45 melanoma 30.7 VIM MDM2 MAGEA1 KIT IGF1R CTNNB1
46 extraosseous osteosarcoma 30.7 SSX1 MDM2
47 endosalpingiosis 30.6 MUC1 KRT7 CALB2
48 spindle cell thymoma 30.6 MUC1 CALB2
49 pericardium cancer 30.6 KRT7 KRT19 CALB2
50 heart sarcoma 30.6 SSX2 SSX1 MDM2 KIT

Graphical network of the top 20 diseases related to Sarcoma, Synovial:



Diseases related to Sarcoma, Synovial

Symptoms & Phenotypes for Sarcoma, Synovial

Human phenotypes related to Sarcoma, Synovial:

31
# Description HPO Frequency HPO Source Accession
1 synovial sarcoma 31 HP:0012570

Clinical features from OMIM®:

300813 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Sarcoma, Synovial:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.61 CDH1 CTNNB1 FLI1 IGF1R KIT KRT19
2 neoplasm MP:0002006 9.17 CDH1 CTNNB1 FLI1 IGF1R KIT KRT19

Drugs & Therapeutics for Sarcoma, Synovial

Drugs for Sarcoma, Synovial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Idarubicin Approved Phase 3 58957-92-9 42890
4
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
5
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
6
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
7
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
8
Trofosfamide Investigational Phase 3 22089-22-1
9 Antibiotics, Antitubercular Phase 3
10 Etoposide phosphate Phase 3
11 Anti-Bacterial Agents Phase 3
12
Liposomal doxorubicin Phase 2, Phase 3 31703
13
Isophosphamide mustard Phase 2, Phase 3 100427
14 Vaccines Phase 3
15
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 6436030 5284616
16
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
17
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
20
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
21
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
22
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
23
ramucirumab Approved, Investigational Phase 1, Phase 2 947687-13-0
24
nivolumab Approved Phase 1, Phase 2 946414-94-4
25
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668
26
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
27
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
28
Adenosine Approved, Investigational Phase 2 58-61-7 60961
29
Mesna Approved, Investigational Phase 2 3375-50-6 598
30
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
31
Ipilimumab Approved Phase 2 477202-00-9
32
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
33
Lysine Approved, Nutraceutical Phase 2 56-87-1 5962
34
Lorvotuzumab mertansine Investigational Phase 2 1008106-64-6
35
Varespladib methyl Investigational Phase 2 172733-08-3
36 Imatinib Mesylate Phase 2 220127-57-1 123596
37 Protein Kinase Inhibitors Phase 2
38 Anti-Infective Agents Phase 2
39 Antiviral Agents Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Epothilones Phase 2
42 Lactams Phase 2
43 Epothilone B Phase 2
44 3-Iodobenzylguanidine Phase 2
45 Antimetabolites Phase 1, Phase 2
46 Protective Agents Phase 2
47 Tubulin Modulators Phase 2
48 Antimitotic Agents Phase 2
49 Maytansine Phase 2
50 Ado-trastuzumab emtansine Phase 2

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL3818;Dacarbazine;AL3818 or placebo
3 A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults Active, not recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
4 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
5 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702) Terminated NCT03520959 Phase 3
6 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
7 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
8 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
9 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
10 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases Completed NCT02181829 Phase 2
11 A Phase 1b/2 Study of Imatinib in Combination With Everolimus in Synovial Sarcoma Completed NCT01281865 Phase 1, Phase 2 everolimus;imatinib mesylate
12 Phase II Study Of Iressa (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1 Completed NCT00052754 Phase 2 gefitinib
13 Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00104949 Phase 2
14 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
15 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
16 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
17 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
18 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
19 A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors Completed NCT00030667 Phase 2 imatinib mesylate
20 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
21 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
22 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
23 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
24 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
25 A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma Recruiting NCT04356872 Phase 2 Sintilimab;Doxorubicin Hydrochloride;Ifosfamide
26 A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Recruiting NCT04044768 Phase 2
27 A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma Recruiting NCT04145700 Phase 1, Phase 2 Ramucirumab;Gemcitabine;Docetaxel
28 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
29 Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies Recruiting NCT03638206 Phase 1, Phase 2
30 Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study Recruiting NCT02875548 Phase 2 Tazemetostat
31 A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors Recruiting NCT03425279 Phase 1, Phase 2
32 Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial Sarcoma Active, not recruiting NCT03250325 Phase 1, Phase 2 Cyclophosphamide
33 A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2) Active, not recruiting NCT03063632 Phase 2
34 A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
35 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Active, not recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
36 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
37 A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies Active, not recruiting NCT02650986 Phase 1, Phase 2 Cyclophosphamide;Decitabine
38 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
39 A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
40 A Phase II Study of Anti-CTLA4 Antibody in Advanced Synovial Sarcoma Patients Terminated NCT00140855 Phase 2 Anti-CTLA4 (monoclonal antibody MDX-010)
41 A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma Terminated NCT00543712 Phase 2 PRO95780
42 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 Terminated NCT02609984 Phase 2
43 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas. Terminated NCT00642941 Phase 2 RG1507
44 Open-Label Phase 1b/2a Clinical Trial to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells (GSK3377794) in Combination With Anti-Cancer Agents Including Pembrolizumab in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Synovial Sarcoma Withdrawn NCT03697824 Phase 2 GSK3377794;Pembrolizumab;Fludarabine;Cyclophosphamide
45 Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1 Unknown status NCT02457650 Phase 1 Cyclophosphamide;Fludarabine
46 A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed Neuroblastoma and Sarcoma. Completed NCT01241162 Phase 1
47 A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma. Completed NCT01477021 Phase 1 cyclophosphamide
48 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Completed NCT01343043 Phase 1
49 A Randomized Trial of Filgrastim-SD/01 vs. Filgrastim in Newly Diagnosed Children and Young Adults With Sarcoma Treated With Dose-Intensive Chemotherapy Completed NCT00004853 Phase 1
50 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride

Search NIH Clinical Center for Sarcoma, Synovial

Cochrane evidence based reviews: sarcoma, synovial

Genetic Tests for Sarcoma, Synovial

Genetic tests related to Sarcoma, Synovial:

# Genetic test Affiliating Genes
1 Synovial Sarcoma 29 SSX1 SSX2

Anatomical Context for Sarcoma, Synovial

MalaCards organs/tissues related to Sarcoma, Synovial:

40
Bone, Lung, Kidney, T Cells, Heart, Bone Marrow, Thyroid

Publications for Sarcoma, Synovial

Articles related to Sarcoma, Synovial:

(show top 50) (show all 3478)
# Title Authors PMID Year
1
The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. 57 61
12173050 2002
2
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. 57 61
11782370 2002
3
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. 61 57
9428816 1998
4
Localization of X chromosome short arm markers relative to synovial sarcoma- and renal adenocarcinoma-associated translocation breakpoints. 61 57
8406438 1993
5
Localization of the synovial sarcoma t(X;18)(p11.2;q11.2) breakpoint by fluorescence in situ hybridization. 61 57
1338692 1992
6
A synovial sarcoma with t(X;18)(p11;q11) in a patient with Turner's syndrome. 61 57
1373322 1992
7
Translocation X;18 and insertion 15;11 in a case of synovial sarcoma. 57 61
2825963 1988
8
Another synovial sarcoma with t(X;18) 57 61
2822225 1987
9
Chromosomal changes in soft-tissue sarcomas. A new diagnostic parameter. 61 57
2823744 1987
10
A consistent chromosome translocation in synovial sarcoma. 57 61
3030536 1987
11
Translocation (X;18) in a synovial sarcoma. 61 57
3030537 1987
12
Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. 57 61
3031659 1987
13
Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression. 54 61
20082858 2010
14
Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. 54 61
19809272 2009
15
Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis. 61 54
20126590 2009
16
Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. 61 54
19936258 2009
17
Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma. 61 54
19602458 2009
18
Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion. 61 54
19649286 2009
19
Human synovial sarcoma proto-oncogene Syt is essential for early embryonic development through the regulation of cell migration. 54 61
19333234 2009
20
Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction. 54 61
19081178 2009
21
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. 61 54
18855347 2008
22
Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. 54 61
18992642 2008
23
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. 61 54
18519690 2008
24
Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. 54 61
18267106 2008
25
The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. 54 61
17667940 2008
26
Expression of MYCN in pediatric synovial sarcoma. 54 61
17464317 2007
27
[Roles of immunohistochemistry and detection of SYT-SSX fusion gene in diagnosis of synovial sarcoma]. 54 61
17845763 2007
28
Opportunities for improving the therapeutic ratio for patients with sarcoma. 61 54
17540303 2007
29
Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. 61 54
17334346 2007
30
Modeling synovial sarcoma: timing is everything. 61 54
17418406 2007
31
The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. 61 54
17101797 2007
32
The (epi)genetics of human synovial sarcoma. 61 54
17117414 2007
33
Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression. 61 54
17197923 2007
34
Primary synovial sarcoma in fallopian tube: case report and literature review. 54 61
17197895 2007
35
Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3. 61 54
17060315 2006
36
The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. 54 61
17018603 2006
37
Biphasic synovial sarcoma of the abdominal wall. 54 61
16855839 2006
38
Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. 61 54
16849525 2006
39
SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. 61 54
16849535 2006
40
The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. 61 54
16462762 2006
41
Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. 61 54
16679870 2006
42
Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. 61 54
16740029 2006
43
A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. 61 54
16682293 2006
44
Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. 54 61
16528378 2006
45
Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. 61 54
16220269 2006
46
G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. 61 54
16450387 2006
47
Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity. 54 61
16329043 2006
48
IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. 61 54
16247461 2006
49
Synovial sarcoma of the mandible. 54 61
16393257 2006
50
Common origin of the human synovial sarcoma associated SS18 and SS18L1 gene loci. 61 54
16484776 2006

Variations for Sarcoma, Synovial

Cosmic variations for Sarcoma, Synovial:

9 (show top 50) (show all 155)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM151345135 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
2 COSM149585128 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
3 COSM150526369 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
4 COSM109692021 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
5 COSM151979842 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
6 COSM151558671 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
7 COSM150452603 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
8 COSM110179560 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
9 COSM151812183 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
10 COSM151326078 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
11 COSM150961248 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
12 COSM89368484 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
13 COSM150733816 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
14 COSM102378542 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
15 COSM150088852 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
16 COSM150913721 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
17 COSM149957835 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
18 COSM151491624 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
19 COSM151343626 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
20 COSM111887159 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
21 COSM151748866 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
22 COSM150659626 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
23 COSM149384200 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
24 COSM149480779 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
25 COSM111036451 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
26 COSM146867874 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
27 COSM151307809 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
28 COSM111893799 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
29 COSM105888206 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
30 COSM150275123 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
31 COSM150868112 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
32 COSM150310035 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
33 COSM102450835 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
34 COSM146243416 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
35 COSM151827154 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
36 COSM151591559 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
37 COSM150142211 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
38 COSM150814289 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
39 COSM149290749 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
40 COSM106056882 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 12
41 COSM111763021 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 12
42 COSM144313682 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 12
43 COSM105659131 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 12
44 COSM93187807 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 12
45 COSM143375075 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 12
46 COSM105624912 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 12
47 COSM122766413 TP53 soft tissue,upper leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 12
48 COSM145021980 TP53 soft tissue,upper leg,sarcoma,NS c.524A>G p.H175R 17:7674890-7674890 12
49 COSM93215390 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 12
50 COSM143182864 TP53 soft tissue,upper leg,sarcoma,NS c.22C>T p.Q8* 17:7675113-7675113 12

Copy number variations for Sarcoma, Synovial from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 120197 18 21850214 21924609 Translate SS18 Synovial sarcoma

Expression for Sarcoma, Synovial

Search GEO for disease gene expression data for Sarcoma, Synovial.

Pathways for Sarcoma, Synovial

Pathways related to Sarcoma, Synovial according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Sarcoma, Synovial

Cellular components related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 VIM SSX4 SSX3 SSX2 SSX1 SS18
2 flotillin complex GO:0016600 8.62 CTNNB1 CDH1

Biological processes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 entry of bacterium into host cell GO:0035635 9.16 CTNNB1 CDH1
2 viral process GO:0016032 9.1 VIM MDM2 KRT7 KRT19 IGF1R CTNNB1
3 cellular response to indole-3-methanol GO:0071681 8.96 CTNNB1 CDH1

Molecular functions related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 VIM SSX4 SSX3 SSX2 SSX1 SS18

Sources for Sarcoma, Synovial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....